WASHINGTON (FNS) -- Applications to market over-the-counter versions of Rogaine (monoxidil), Tagamet (cimetidine) and Pepcid (famotidine) are pending final review by the Food and Drug Administration. Approval of any of the three applications is considered unlikely, because FDA advisory panels last month recommended against switching the drugs to OTC status. FDA typically, although not always, follows the recommendations of its advisory committees. Rogaine, a product of Upjohn, Kalamazoo, ...
REGISTER TO VIEW THIS ARTICLE - Register for a Free Account
Registering for content on Supermarket News will give youINSTANTaccess to invaluable articles and media content that industry professionals rely on. You will have access to our special reports, feature articles, and industry analysis. It’sFREE, easy and quick. What are you waiting for!In addition you will also receive a complimentary copy of SN's salary survey sent to you by email.
Attention Paid Print Subscribers: While you have already been grantedfreeaccess to SNwe ask that youregister now.We promise it will only take a few minutes! Or visit your profile and add your print magazine account number and zip code.